Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System

por Joshi, Shweta, Durden, Donald L.
Publicado 2019

The differential ability of asparagine and glutamine in promoting the closed/active enzyme conformation rationalizes the Wolinella succinogenes L-asparaginase substrate specificity

por Nguyen, Hien Anh, Durden, Donald L., Lavie, Arnon
Publicado 2017

A PKC-SHP1 signaling axis desensitizes Fcγ receptor signaling by reducing the tyrosine phosphorylation of CBL and regulates FcγR mediated phagocytosis

por Joshi, Shweta, Singh, Alok Ranjan, Zulcic, Muamera, Durden, Donald L
Publicado 2014

Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12) V-Ha-Ras transgenic mouse glioma model

por Singh, Alok R, Joshi, Shweta, George, Elizabeth, Durden, Donald L
Publicado 2014

In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells

por Ozbay, Tuba, Durden, Donald L., Liu, Tongrui, O’Regan, Ruth M., Nahta, Rita
Publicado 2009

The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention

por Peirce, Susan K., Findley, Harry W., Prince, Chengyu, Dasgupta, Anindya, Cooper, Todd, Durden, Donald L.
Publicado 2010

Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targets

por Vann, Kendra R., Pal, Dhananjaya, Morales, Guillermo A., Burgoyne, Adam M., Durden, Donald L., Kutateladze, Tatiana G.
Publicado 2020

Rac2 Controls Tumor Growth, Metastasis and M1-M2 Macrophage Differentiation In Vivo

por Joshi, Shweta, Singh, Alok R., Zulcic, Muamera, Bao, Lei, Messer, Karen, Ideker, Trey, Dutkowski, Janusz, Durden, Donald L.
Publicado 2014

PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells

por Crosswell, Hal E, Dasgupta, Anindya, Alvarado, Carlos S, Watt, Tanya, Christensen, James G, De, Pradip, Durden, Donald L, Findley, Harry W
Publicado 2009

Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release

por Ishii, Yuki, Nhiayi, May Keu, Tse, Edison, Cheng, Jonathan, Massimino, Michele, Durden, Donald L., Vigneri, Paolo, Wang, Jean Y. J.
Publicado 2015

Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype

por Joshi, Shweta, Singh, Alok R., Wong, Simon S., Zulcic, Muamera, Jiang, Min, Pardo, Annie, Selman, Moises, Hagood, James S., Durden, Donald L.
Publicado 2017

Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma

por Chahal, Kirti Kandhwal, Li, Jie, Kufareva, Irina, Parle, Milind, Durden, Donald L., Wechsler-Reya, Robert J., Chen, Clark C., Abagyan, Ruben
Publicado 2019

The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma

por Pal, Dhananjaya, Vann, Kendra R., Joshi, Shweta, Sahar, Namood E., Morales, Guillermo A., El-Gamal, Dalia, Kutateladze, Tatiana G., Durden, Donald L.
Publicado 2021

Amino Acids Regulate Cisplatin Insensitivity in Neuroblastoma

por Gunda, Venugopal, Pathania, Anup S., Chava, Srinivas, Prathipati, Philip, Chaturvedi, Nagendra K., Coulter, Don W., Pandey, Manoj K., Durden, Donald L., Challagundla, Kishore B.
Publicado 2020

PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron

por Acharya, Arpan, Pathania, Anup S., Pandey, Kabita, Thurman, Michellie, Vann, Kendra R., Kutateladze, Tatiana G., Challagundala, Kishore B., Durden, Donald L., Byrareddy, Siddappa N.
Publicado 2022

Heterozygosity for Pten Promotes Tumorigenesis in a Mouse Model of Medulloblastoma

por Castellino, Robert C., Barwick, Benjamin G., Schniederjan, Matthew, Buss, Meghan C., Becher, Oren, Hambardzumyan, Dolores, MacDonald, Tobey J., Brat, Daniel J., Durden, Donald L.
Publicado 2010

A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity

por Burgoyne, Adam M., Vann, Kendra R., Joshi, Shweta, Morales, Guillermo A., Vega, Francisco M., Singh, Alok, Pal, Dhananjaya, Merati, Aran B., Kutateladze, Tatiana G., Durden, Donald L.
Publicado 2020

COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges

por Pathania, Anup S., Prathipati, Philip, Abdul, Bakrudeen AA., Chava, Srinivas, Katta, Santharam S., Gupta, Subash C., Gangula, Pandu R., Pandey, Manoj K., Durden, Donald L., Byrareddy, Siddappa N., Challagundla, Kishore B.
Publicado 2021

PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma

por Singh, Alok R., Joshi, Shweta, Zulcic, Muamera, Alcaraz, Michael, Garlich, Joseph R., Morales, Guillermo A., Cho, Yoon J., Bao, Lei, Levy, Michael L., Newbury, Robert, Malicki, Denise, Messer, Karen, Crawford, John, Durden, Donald L.
Publicado 2016

Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection

por Vann, Kendra R., Acharya, Arpan, Jang, Suk Min, Lachance, Catherine, Zandian, Mohamad, Holt, Tina A., Smith, Audrey L., Pandey, Kabita, Durden, Donald L., El-Gamal, Dalia, Côté, Jacques, Byrareddy, Siddappa N., Kutateladze, Tatiana G.
Publicado 2022